NCT07622940
- Conditions
- Adenocarcinoma Of Esophagus, Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease, Disease Attributes, +4 more
- Locations
-
- Peking University Shenzhen Hospital Shenzhen, Guangdong, China
Clinical trial condition
Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease
Explore clinical trials studying Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease. Study availability and eligibility vary by location and protocol.
1 public trial
1 recruiting study